[Therapeutic advances against thromboembolic disease: II. The use of tissue fibrinolysis activator as a thrombolytic agent].
D000818:Animals; D004285:Dogs; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D010958:Plasminogen / Q000502:physiology; D010960:Plasminogen Activators / Q000502:physiology / Q000627:therapeutic use*; D011817:Rabbits; D013923:Thromboembolism / Q000097:blood / Q000503:physiopathology / Q000517:prevention & control*; D000979:alpha-2-Antiplasmin / Q000502:physiology
D005343:Fibrinolytic Agents; D000979:alpha-2-Antiplasmin; D010958:Plasminogen; D010960:Plasminogen Activators
Avances terapéuticos contra la enfermedad tromboembólica: II. La utilización del activador tisular de la fibrinolisis como agente trombolítico.